摘要
目的:研究酒石酸长春瑞滨脂质微球注射液(NVB-lip)对荷人乳腺癌裸鼠肿瘤生长的影响。方法:35只雌性BALB/c-nu裸鼠,随机分为NVB-lip高(10 mg/kg)、中(5 mg/kg)、低(2.5 mg/kg)剂量组,阳性对照组(酒石酸长春瑞滨注射液,5 mg/kg)和阴性对照组(脂质化空白溶液),每组7只。给裸鼠接种人乳腺癌BCAP-37瘤株,待成瘤后,每只动物每次按0.20 mL经尾静脉注射给药,间隔3-4 d注射1次,每周注射2次,共注射6次。在第1次注射后第4、7、11、14、18和23天时分别称小鼠体质量和测量肿瘤体积,计算得出相对肿瘤体积、相对肿瘤增殖率和肿瘤抑制率。结果:与阴性对照组相比,各组荷瘤裸鼠体质量差异均无统计学意义(P均〉0.05)。NVB-lip各剂量组的相对肿瘤体积和相对肿瘤增殖率显著减小,肿瘤抑制率显著增大,差异均有统计学意义(P〈0.01)。结论:NVB-lip在2.5-10 mg/kg范围内抑瘤作用明显,具有可开发潜力。
OBJECTIVE: To study the effect of vinorelbine tartrate lipid microsphere(NVB-lip) injection on growth of human breast cancer cells in nude mice. METHODS:35 female BALB/c-nu mice were inoculated with human breast cancer BCAP-37 cells. These mice were divided randomly into 5 groups for further treatments:NVB-lip high dose group(NVB-lip 10 mg/kg),medium dose group(NVB-lip 5 mg/kg),low dose group(NVB-lip 2.5 mg/kg),positive drug control group(NVB-free 5 mg/kg) and negative control group(only lipid microsphere). There were 7 mice each group. Injection with NVB-lip was done after 6-8 days when the tumors shaped. NVB-lip was injected intravenously every 3 or 4 days each week for 6 times in total. Weights and tumor volumes(V T) of mice were observed and measured on No. 4,7,11,14,18 and 23 days from the first injection. Relative tumor volumn(V RT),relative tumor proliferation rate and tumor inhibition rate were calculated. RESULTS:The weights of nude mice for different groups increased slowly but the differences were not statistically significant. Compared with the negative group,the V RT and relative tumor proliferation rates of NVB-lip groups were reduced but tumor inhibition rate was increased. The differences were statistically significant(P〈0.01). CONCLUSION:The inhibition of NVB-lip high dose group(2.5-10 mg/kg) was more obviously than that of the other groups. NVB-lip may h ave c linical a pplications.
出处
《癌变.畸变.突变》
CAS
CSCD
2016年第2期103-106,共4页
Carcinogenesis,Teratogenesis & Mutagenesis
关键词
酒石酸长春瑞滨脂质微球注射液
裸鼠
人乳腺癌
肿瘤抑制
vinorelbine tartrate lipid microsphere injection
nude mice
human breast cancer
tumor inhibition